{"schema":"https://ver.cy/schemas/card/1.0.0","id":"vr.tr.otilonium-bromide","code":"thing-q920900","url":"https://ver.cy/models/thing/q920900/","name":"otilonium bromide","alternateNames":[],"kind":"thing","status":"published","version":"0.1.0-research.1","language":"en","classifiers":{"family":"Thing Registry","category":"Physical world and living systems","entryKind":"thing","plane":"PHY","domain":["PHY.MAT"],"industry":[],"navPath":"","tags":[],"facets":{}},"whatItIs":"Otilonium bromide is a synthetic quaternary ammonium bromide salt used as a gastrointestinal antispasmodic to reduce intestinal smooth-muscle contraction.","purpose":"Enable an agent to recognise otilonium bromide, assess a material lot and determine its suitability for a documented research or pharmaceutical use.","scope":{"in":["Otilonium cation and bromide counterion identity and stoichiometry","Lot-specific assay, impurities, water content and material grade","Solid form, dissolution behaviour and stability under stated conditions","Evidence for gastrointestinal smooth-muscle activity and disposition","Substance handling requirements and links to jurisdiction-specific regulatory records"],"out":["Finished tablets, brands, packaging and excipient formulations","Patient diagnosis, prescribing, dose selection and treatment monitoring","Manufacturing equipment and complete synthesis processes","Irritable bowel syndrome as a disease model","Other antispasmodics or other salts of otilonium as interchangeable substances"],"boundaries":[]},"distinguishingFeatures":["Match the complete salt to C29H43BrN2O4 and PubChem CID 72092; the isolated otilonium cation has a separate record, CID 72093. [PubChem salt record](https://pubchem.ncbi.nlm.nih.gov/compound/Otilonium-Bromide), [cation record](https://pubchem.ncbi.nlm.nih.gov/compound/Otilonium)","Confirm CAS 26095-59-0 and a monobromide composition rather than accepting an unspecified otilonium name. [Supplier identity specification](https://cdn.caymanchem.com/cdn/insert/29907.pdf)","Check the quaternary ammonium structure with its octyloxy-substituted benzamide and ester linkage; a bromide counterion or antispasmodic label alone cannot establish identity. [Structural specification](https://cdn.caymanchem.com/cdn/insert/29907.pdf)","Distinguish a characterised substance lot from a finished medicine: shared active-ingredient identity does not establish equivalent formulation, purity or permitted use."],"structure":{"bundles":[{"id":"salt-identity","name":"Salt identity","description":"Establish whether a record or sample represents the registered otilonium bromide substance.","layers":[{"id":"molecular-recognition","name":"Molecular recognition","description":"Connect the name to the organic structure and counterion.","findings":[{"id":"complete-salt-match","name":"Complete salt match","description":"Require evidence for both the otilonium component and bromide, rather than relying on a name or organic-ion signal alone.","questions":[{"text":"Which structural identifier explicitly represents both otilonium and bromide?","id":"complete-salt-match-q01","kind":"definition"},{"text":"Which analytical results establish the organic identity and counterion composition?","id":"complete-salt-match-q02","kind":"measurement"}]}]},{"id":"registry-boundaries","name":"Registry boundaries","description":"Resolve names and external identifiers without expanding the registered concept.","findings":[{"id":"substance-versus-product","name":"Substance versus product","description":"Attach external records only after checking whether they describe the salt, cation or a formulated medicine.","questions":[{"text":"Does each linked identifier denote the complete bromide salt?","id":"substance-versus-product-q01","kind":"boundary"},{"text":"What source supports mapping an alternative spelling or supplier name to this entry?","id":"substance-versus-product-q02","kind":"provenance"}]}]}]},{"id":"lot-composition-and-quality","name":"Lot composition and quality","description":"Determine what a physical lot contains and whether its evidence supports the intended use.","layers":[{"id":"content-accounting","name":"Content accounting","description":"Record assay, water and counterion measurements on compatible bases.","findings":[{"id":"usable-salt-content","name":"Usable salt content","description":"Keep mass assay separate from chromatographic purity and distinguish salt-equivalent from cation-equivalent quantities.","questions":[{"text":"Is the reported percentage a mass assay or chromatographic area percentage, and on what moisture basis?","id":"usable-salt-content-q01","kind":"measurement"},{"text":"Is the requested concentration expressed as complete otilonium bromide or otilonium cation equivalents?","id":"usable-salt-content-q02","kind":"boundary"}]}]},{"id":"impurities-and-qualification","name":"Impurities and qualification","description":"Connect impurity results and grade claims to a lot-specific specification.","findings":[{"id":"qualified-material","name":"Qualified material","description":"Evaluate related substances, residual solvents and applicable contaminants using documented methods and acceptance criteria.","questions":[{"text":"Which otilonium-related impurities are identified, quantified or left unresolved by the analytical method?","id":"qualified-material-q01","kind":"measurement"},{"text":"Which certificate, specification and qualification records justify using this lot for the proposed purpose?","id":"qualified-material-q02","kind":"action"}]}]}]},{"id":"physical-state-and-preparation","name":"Physical state and preparation","description":"Represent the material form and conditions needed to obtain and preserve a defined preparation.","layers":[{"id":"solid-state-evidence","name":"Solid-state evidence","description":"Characterise the actual solid without assuming a universal crystal form or thermal constant.","findings":[{"id":"form-and-thermal-events","name":"Form and thermal events","description":"Record crystal-form evidence, water or solvent inclusion and measured thermal events for the material examined.","questions":[{"text":"What measurements establish the solid form and any associated water or solvent?","id":"form-and-thermal-events-q01","kind":"measurement"},{"text":"Does a reported thermal event represent melting, desolvation, a transition or decomposition?","id":"form-and-thermal-events-q02","kind":"boundary"}]}]},{"id":"solution-and-storage","name":"Solution and storage","description":"Tie preparation feasibility and useful lifetime to solvent, concentration and environmental conditions.","findings":[{"id":"conditioned-preparation","name":"Conditioned preparation","description":"Supplier guidance reports solvent-specific solubility and separate limits for aqueous preparations; retain its product scope. [Preparation guidance](https://cdn.caymanchem.com/cdn/insert/29907.pdf)","questions":[{"text":"At the intended pH, solvent composition and temperature, what dissolved concentration is demonstrated?","id":"conditioned-preparation-q01","kind":"measurement"},{"text":"What stability evidence supports the storage interval for this solid lot or prepared solution?","id":"conditioned-preparation-q02","kind":"provenance"},{"text":"What precipitation or analytical change requires rejecting or requalifying the preparation?","id":"conditioned-preparation-q03","kind":"action"}]}]}]},{"id":"gastrointestinal-pharmacology","name":"Gastrointestinal pharmacology","description":"Organise evidence connecting otilonium bromide exposure to intestinal smooth-muscle responses.","layers":[{"id":"mechanisms-and-assays","name":"Mechanisms and assays","description":"Preserve experimental context for channel and receptor-response evidence.","findings":[{"id":"multiple-functional-actions","name":"Multiple functional actions","description":"A study using human cultured colonic smooth-muscle cells and rat colonic strips reports inhibition of calcium-channel, muscarinic and tachykininergic responses. [Primary study](https://pubmed.ncbi.nlm.nih.gov/23941257/)","questions":[{"text":"Which target, stimulus, species and preparation support each attributed action?","id":"multiple-functional-actions-q01","kind":"provenance"},{"text":"What concentration-response endpoint was measured, and how was dissolved exposure verified?","id":"multiple-functional-actions-q02","kind":"measurement"},{"text":"Does the experiment establish direct target interaction or only inhibition of a downstream response?","id":"multiple-functional-actions-q03","kind":"boundary"}]}]},{"id":"exposure-and-translation","name":"Exposure and translation","description":"Relate experimental activity to route-specific tissue and systemic exposure.","findings":[{"id":"local-versus-systemic-exposure","name":"Local versus systemic exposure","description":"Experimental literature describes poor absorption and gastrointestinally concentrated exposure; quantitative transfer to a particular human use requires matching evidence. [Primary pharmacology study](https://pmc.ncbi.nlm.nih.gov/articles/PMC2867415/)","questions":[{"text":"Which route, species, formulation and sampling method support an absorption or tissue-exposure claim?","id":"local-versus-systemic-exposure-q01","kind":"provenance"},{"text":"Are measured concentrations total, unbound, plasma or tissue values, and are they comparable to the assay concentrations?","id":"local-versus-systemic-exposure-q02","kind":"measurement"},{"text":"What additional clinical evidence is needed before a mechanistic result supports a therapeutic claim?","id":"local-versus-systemic-exposure-q03","kind":"boundary"}]}]}]},{"id":"handling-and-use-authority","name":"Handling and use authority","description":"Connect the substance to evidence governing laboratory handling and pharmaceutical use.","layers":[{"id":"material-handling","name":"Material handling","description":"Identify applicable controls for the particular powder or solution.","findings":[{"id":"documented-hazard-controls","name":"Documented hazard controls","description":"Require an applicable SDS and distinguish an absent exposure limit from a demonstrated safe exposure.","questions":[{"text":"Which dated SDS and jurisdiction support the assigned GHS classification for this material?","id":"documented-hazard-controls-q01","kind":"provenance"},{"text":"Is an occupational exposure limit established, or is its status unverified?","id":"documented-hazard-controls-q02","kind":"measurement"},{"text":"Which documented controls govern weighing, solution preparation, spills and disposal?","id":"documented-hazard-controls-q03","kind":"action"}]}]},{"id":"pharmaceutical-use-boundary","name":"Pharmaceutical use boundary","description":"Link material suitability to the proposed activity and relevant authority.","findings":[{"id":"grade-and-authorisation","name":"Grade and authorisation","description":"A supplier's research material is explicitly restricted to research use; that record cannot establish pharmaceutical suitability. [Supplier use restriction](https://cdn.caymanchem.com/cdn/insert/29907.pdf)","questions":[{"text":"What evidence qualifies this specific lot for research, pharmaceutical manufacture or another stated activity?","id":"grade-and-authorisation-q01","kind":"action"},{"text":"Which jurisdiction-specific authorisation belongs to a finished medicine rather than to this substance record?","id":"grade-and-authorisation-q02","kind":"boundary"}]}]}]},{"id":"evidence-and-external-alignment","name":"Evidence and external alignment","description":"What the world already says about this thing, gathered so the model can be checked against it.","layers":[{"id":"reported-evidence","name":"Reported evidence","description":"Findings from the breadth pass, kept separate from the structural claims.","findings":[{"id":"evidence-confidence-notes","name":"Check these first","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these check these first hold for the sense of otilonium bromide this model covers, and on what evidence?","id":"evidence-confidence-notes-q01","kind":"provenance"}]},{"id":"evidence-identifiers","name":"Identifiers and schemes","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these identifiers and schemes hold for the sense of otilonium bromide this model covers, and on what evidence?","id":"evidence-identifiers-q01","kind":"provenance"}]},{"id":"evidence-real-world-use","name":"Real-world use","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these real-world use hold for the sense of otilonium bromide this model covers, and on what evidence?","id":"evidence-real-world-use-q01","kind":"provenance"}]},{"id":"evidence-measurements","name":"Typical measurements","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these typical measurements hold for the sense of otilonium bromide this model covers, and on what evidence?","id":"evidence-measurements-q01","kind":"provenance"}]},{"id":"evidence-failure-modes-and-hazards","name":"Failure modes and hazards","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these failure modes and hazards hold for the sense of otilonium bromide this model covers, and on what evidence?","id":"evidence-failure-modes-and-hazards-q01","kind":"provenance"}]},{"id":"evidence-regional-variation","name":"Regional variation","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these regional variation hold for the sense of otilonium bromide this model covers, and on what evidence?","id":"evidence-regional-variation-q01","kind":"provenance"}]},{"id":"evidence-neighbours","name":"Neighbouring kinds and how to tell them apart","description":"Recalled without web access and unsourced; every item is a lead to verify.","questions":[{"text":"Which of these neighbouring kinds and how to tell them apart hold for the sense of otilonium bromide this model covers, and on what evidence?","id":"evidence-neighbours-q01","kind":"provenance"}]}]}]}]},"agentConduct":{"may":["Identify otilonium bromide by name, identifiers and documented properties, citing sources.","Report approved uses in a stated country from official product information.","Check a material lot's certificate of analysis against its specification."],"mustNot":["Recommend it or a dose for a particular person's abdominal symptoms.","Suggest it as a substitute for medical assessment of persistent abdominal pain.","Supply it outside lawful pharmaceutical channels."],"requiresHuman":["Any decision to give it to a patient.","Releasing or destroying a material lot."]},"ethics":{"considerations":["Self-treating abdominal pain can hide serious disease.","Functional bowel disorders are often dismissed; honest information supports patients."],"affectedParties":["Patients with bowel disorders","Prescribers and pharmacists"]},"owners":{"steward":"The marketing authorization holder for each medicine; the national medicines regulator oversees it.","roles":[],"masterSystems":["National medicines registers"]},"relations":[{"target":"Q11173","type":"parent","note":"registry parent class"}],"interaction":{"identity":{"applicability":"required","items":["Vercy registry: vr.tr.otilonium-bromide","Wikidata: Q920900 (https://www.wikidata.org/wiki/Q920900)"]},"properties":{"applicability":"required","items":["Salt identity: Otilonium bromide; C29H43BrN2O4; CAS 26095-59-0","Salt formula mass: 563.6 g/mol","Otilonium-to-bromide ratio: mol/mol; identity target 1:1","Assay and reporting basis: % w/w; as received, dry or anhydrous basis; method and uncertainty","Impurity profile: Individual and total related substances in %; residual solvents in ppm; method-specific limits","Physical form and water content: Observed phase; characterised crystal form or unknown; water % w/w","Conditional solubility: mg/mL or mol/L with solvent, pH, temperature and equilibration method","Thermal behaviour: Melting, transition or decomposition temperature in °C with method; boiling point only if substantiated","Functional potency: IC50 or EC50 in mol/L with target, species, preparation and endpoint","Disposition evidence: Linked studies with route, species, formulation, tissue and sampling interval","Use eligibility: Research grade, qualified pharmaceutical material, quarantined or unverified; supporting records","Hazard and regulatory identity: Dated SDS, GHS jurisdiction, exposure-limit source, EC record if verified and applicable medicine records"]},"recognition":{"applicability":"required","items":["Identity rests on the label, batch record and certificate of analysis, not appearance."]},"capabilities":{"applicability":"required","items":["Reconcile an incoming material record with the complete otilonium bromide identity.","Evaluate lot evidence against a stated research or pharmaceutical specification.","Calculate assay-corrected salt concentrations with explicit water and reporting bases.","Select documented dissolution and storage conditions for a particular preparation.","Compare smooth-muscle activity studies while preserving assay and exposure differences.","Flag missing safety, quality or regulatory evidence before assigning a material to an intended use."]},"hazards":{"applicability":"required","items":["Masking of symptoms of serious abdominal disease.","Substandard or falsified products."]},"interfaces":{"applicability":"required","items":["ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation."]},"context":{"applicability":"required","items":["Otilonium bromide is encountered in pharmaceutical formulations and research concerning intestinal smooth-muscle activity.","Material lots are assessed for identity, purity and conformity to specifications for their documented pharmaceutical or research use."]}},"sources":[{"title":"Wikidata item Q920900: otilonium bromide","url":"https://www.wikidata.org/wiki/Q920900","note":"identity and sense of the item"},{"title":"Wikipedia: Otilonium bromide","url":"https://en.wikipedia.org/wiki/Otilonium_bromide","note":"general description of the item"}],"openQuestions":["Which authoritative EC identifier, pharmacopoeial monographs and jurisdiction-specific substance records apply to otilonium bromide?","Which solid forms, hydration states and validated melting or decomposition measurements are established, and is a boiling point physically meaningful?","Which validated assay, impurity identities and acceptance limits distinguish qualified pharmaceutical material from research grades?","What current GHS classifications, occupational exposure limits and environmental disposal requirements are supported by applicable authoritative records?","What human tissue-exposure and clinical evidence establishes the relevance of individual channel and receptor effects under authorised conditions of use?"],"resources":{"spec":"/models/things/publications/thing-q920900/spec.json"},"provenance":{"origin":"thing registry research (pass 2)","builtFrom":["models/things/publications/thing-q920900/spec.json"],"providers":["Codex"],"researchStatus":"unreviewed","generatedAt":"2026-09-12T11:49:23Z","builder":"tools/build_cards.py@1.0.0"},"completeness":{"sections":{"classifiers":"filled","whatItIs":"filled","purpose":"filled","distinguishingFeatures":"filled","structure":"filled","agentConduct":"filled","ethics":"filled","owners":"filled","relations":"filled","interaction.identity":"filled","interaction.properties":"filled","interaction.recognition":"filled","interaction.capabilities":"filled","interaction.hazards":"filled","interaction.interfaces":"filled","interaction.context":"filled","sources":"filled"},"notes":{"_gate":"Published through the thing publication gate 1.0 on 2026-10-07T10:10:33+00:00: completeness 1.00; sense: Wikidata description; 2 live sources; review by codex: pass"},"score":1.0}}